Join Now                                         Blog   LinkedIn   Twitter 

Towards a new dementia treatment, 20/03/18, London

Policy Conference
Join us on 20 March 2018 for Alzheimer’s Research UK’s inaugural policy conference “Looking Forward: Towards a new Dementia Treatment”.

Just minutes from the Houses of Parliament, in the Queen Elizabeth Conference Centre in Westminster, this half-day conference on 20 March 2018 will examine the political and systemic challenges that still lie ahead if we are to find the first life-changing treatment for dementia by 2025.

Running in parallel to ARUK’s flagship research conference, this will be an exciting opportunity to explore the political and policy environment in which today’s groundbreaking dementia research is taking place.

Delegates will hear key academics and industry experts discussing the momentum that has built around dementia research in the UK, what else the sector needs to find a life-changing treatment and, once we have a treatment, how we work together to ensure it reaches patients.

Looking Forward: Towards a new Dementia Treatment is the conference for anyone with an interest in the future of dementia research, whether you work in health and social care, government, academia, policy or research. Delegates already attending the research conference are welcome to join us for one or both sessions.

Date & time: Tuesday 20 March 2018. 1:45pm – 5:30pm

Venue: QE II Conference Centre, Victoria Street, Westminster, London

Cost: £35 + VAT

Register for the Alzheimer’s Research UK policy conference here.

Session 1: Maintaining the political focus on dementia research.

With keynote address speaker to be confirmed.

Session 2: What does dementia research need to get a life changing treatment?
Over the last few years significant progress has been made in the search for a life-changing treatment for dementia. A strong life sciences community and support from the Government has enabled the UK to become a global leader in making advances in dementia research.

However, the UK faces significant social, economic and political challenges. The challenge for the sector is to navigate through these to find opportunities so we can continue to accelerate towards a new treatment.

This session will examine some of the opportunities and threats facing the sector and focus on what the sector needs to get to a new treatment by 2025.

With confirmed speakers:

Prof Graeme Reid. Professor of science and research policy at UCL, Graeme has spent many years at the interface between science and government.
Prof Martin Rossor. NIHR National Director for Dementia Research, Martin will discuss how the NHS can best support the discovery of life changing treatments.
Richard Torbett. Director of Commercial Policy, Association of the British Pharmaceutical Industry (ABPI)
Prof Hugh Perry. Professor of Experimental Neuropathology, University of Southampton

Session 3: Getting a new treatment to patients

Experts from the London School of Economics have analysed the potential economic impact should a new treatment for dementia be developed. Hear how this analysis can help to inform how we get a treatment to patients when one becomes available, and explore how we can better prepare the UK healthcare system for a new treatment to come on the market.

This session will also focus on the importance of earlier diagnosis to the treatment of dementia and how ARUK is leading the way in finding new technological approaches to early dementia diagnosis.

With confirmed speakers:

Prof Martin Knapp. Professor of Social Policy at LSE, Martin will discuss what the economic modelling tells us about the potential impact of a new treatment for dementia.
Hilary Evans. Chief Executive of Alzheimer’s Research UK, Hilary will consider the role of charities in helping prepare for a new treatment.
Adam Graham. Adam will offer his insight into what a life changing treatment would mean for those living with dementia and their families.
Prof Jonathan Schott. Clinical neurologist at the UCL Dementia research centre, Jonathan will a clinical perspective on what a new treatment would mean and why it’s important to start considering the impact of new treatments now.
Prof Alastair Burns. Professor of Old Age Psychiatry at The University of Manchester, National Clinical Director for Dementia and National Clinical Director for Mental Health in Older People at NHS England. Alastair will consider what the NHS needs to do to better prepare for a new treatment.
Sarah Neville. Sarah is Global Pharmaceuticals Editor at the Financial Times, covering health and the pharmaceuticals industry.
Delegates attending the research conference are welcome to attend the policy conference. Please register free of charge.

Date & time: Tuesday 20 March 2018. 1:45pm – 5:30pm

Venue: QE II Conference Centre, Victoria Street, Westminster, London

Cost: £35


Search (mobile)

We use cookies to improve our website and your experience. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site